アルツハイマー病における細胞型特異的なメタボリックマスターレギュレータの体系的な特徴付け
Yunguang Qiu1,2, Yuan Hou1,2, Liam Wetzel3
1Cleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Research square
|September 2, 2025
まとめ
アルツハイマー病は脳細胞の代謝を変化させ ニューロンがエネルギー消費を減らし マイクログリアが増加させます scFUMESという新しいアルゴリズムは アルツハイマー病の標的治療のための 重要な代謝調節物質を特定します
科学分野:
- 神経科学
- メタボロミクス
- システム生物学
背景:
- アルツハイマー病 (AD) には代謝異質性がありますが,細胞タイプ特有の代謝ダイナミクスとレギュレータネットワークは十分に理解されていません.
- ニューロン代謝はADで低下し,マイクログリア代謝は神経炎症に関連して増加する.
研究 の 目的:
- アルツハイマー病の脳細胞タイプに特有のメタボリックレギュレータを特定する.
- ADの代謝変化のメタボリート-センサネットワークの基礎を解明する.
主な方法:
- scFUMES (単細胞機能代謝体センサー) を開発し,単細胞RNAシーケンシング,インタラクトミクス,ゲノミクス,トランスクリプトミクス,およびメタボロミクスを統合した.
- ヒトの脳バイオバンクに scFUMESを適用した.
主要な成果:
- scFUMESでは,ADに関連した代謝調節物質が数百種類特定され,神経細胞とマイクログリアが最も多くの相互作用を示した.
- ADの重症度,性別,およびAPOEのゲノタイプにおける遺伝子情報に基づくマスターレギュレータ (例えば,ミクログリアのPPARD-グリセロール) を特定した.
- 2つの予測された相互作用 (ニューロンパルミチン酸/FABP3,インドル3プロピオン酸/KAT1) を検証し,ADの病理性タウ種を減少させた.
結論:
- scFUMESは,アルツハイマー病における細胞型特異的なメタボリック・マスター・レギュレータを効果的に特定します.
- 細胞の代謝異質性とADや他の神経変性疾患に対する潜在的代謝標的治療戦略に関する洞察を提供します.
さらに関連する動画
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
976
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
626
関連する概念動画
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Master Transcription Regulators
7.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Role of Neurotransmitters in Memory
964
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
964
